Study using Nexalin’s proprietary DIFS ™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up ...
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation...
U.S. House Appropriations Committee report language directs VA to support additional research evaluating non-invasive deep brain neurostimulation technologies for veterans with treatment-resistant traumatic...
HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...
Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group ...
HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW). The exclusive...
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive...
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed...